Plasma beta-endorphin concentrations are increased in chronic obstructive pulmonary disease patients

Scand J Clin Lab Invest. 2000 Oct;60(6):501-6. doi: 10.1080/003655100448482.

Abstract

The present study is concerned with plasma beta-endorphin and glucose tolerance in patients with chronic obstructive pulmonary disease (COPD). Plasma beta-endorphin, glucagon and insulin concentrations were measured during an oral glucose tolerance test in 20 COPD patients and in 18 age-matched healthy controls (mean age 62 years). Seven patients had a moderate COPD (group I) and seven a severe COPD (group II). The remaining six severe COPD patients received long-term oxygen therapy (group III). We found that fasting levels of beta-endorphin were significantly increased in all patient groups compared to healthy controls (p < 0.01, 0.05 and 0.005, respectively). Six of the 13 severely diseased COPD patients had impaired glucose tolerance. Plasma beta-endorphin levels decreased significantly during OGTT in the COPD patients (p < 0.05). Fasting beta-endorphin levels were higher in patients with impaired glucose tolerance than in those patients with normal OGTT (42.0 pmol/L +/- 11.4 SD versus 34.8 +/- 10.2). However, this difference was not statistically significant. In conclusion, this study showed that beta-endorphin concentrations are increased in COPD patients whether or not they receive oxygen therapy.

MeSH terms

  • Blood Glucose / analysis
  • Case-Control Studies
  • Female
  • Glucagon / blood
  • Glucose Tolerance Test
  • Humans
  • Insulin / blood
  • Lung Diseases, Obstructive / blood*
  • Male
  • Middle Aged
  • beta-Endorphin / blood*

Substances

  • Blood Glucose
  • Insulin
  • beta-Endorphin
  • Glucagon